There are better solutions to the "reproducibility crisis" in research, according to an editorial published today.
Should an academic institution refund its financial payment if the basic science or pre-clinical results prove to be irreproducible?
Such an "incentive-based approach" for improving data reproducibility was recently proposed by a senior executive at Merck, although the idea is said not to represent the company's position.
But in an editorial published by The BMJ today, Eric Topol, Director of Scripps Translational Science Institute in California, argues that there are better solutions to the "reproducibility crisis" in research.